PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB
Rheumatoid arthritis (RA) is one of the most common and severe chronic inflammatory diseases. The paper reviews the recent studies evaluating the efficacy of rituximab (MabThera®), chimeric anti-CD20 monoclonal antibodies in B cells, in patients with RA. It has been shown that Rituximab is an extrem...
Saved in:
Main Author: | Evgeni Lvovich Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2009-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/261 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RANGE AT RHEUMATOID ARTHRITIS AGAINST THERAPY THE RITUKSIMABY
by: Vadim Ivanovich Mazurov, et al.
Published: (2022-05-01) -
Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real clinical practice in Kazakhstan
by: G. A. Togizbayev, et al.
Published: (2020-12-01) -
The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01) -
Antikeratin antibodies in rheumatoid arthritis
by: J Zabek
Published: (2003-02-01) -
External respiration disturbances in patients with rheumatoid arthritis
by: K A Bijbolatova, et al.
Published: (2008-04-01)